BACK

Oncology References

REFERENCES IN CHRONOLOGICAL ORDER

(Updated on 25 January 2012)

Year of publication:
» 2012
» 2011
» 2010
» 2009
» 2008
» 2007
» 2006
» 2005
» 2004
» 2003
» 1999 – 2002

Ari F, Napieralski R, Ulukaya E, Dere E, Colling C, Honert K, Krüger A, Kiechle M, Schmitt M (2011)
Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine
Cell Biochem Funct 2011, 29(8), 651-9
»Abstract

Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I (2011)
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Ann Oncol. 2011, , [Epub ahead of print]
»Abstract

Barut O, Vural P, Sirin S, Aydin S, Dizdar Y (2011)
The oxidant/antioxidant status and cell death mode in oral squamous cell carcinoma
Acta Odontol Scand. 2011, , [Epub ahead of print]
»Abstract

Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M. (2011)
Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Cancer Chemother Pharmacol 2011, 68(2), 309-16
»Abstract

Choudhary V, Kaddour-Djebbar I, Lakshmikanthan V, Ghazaly T, Thangjam GS, Sreekumar A, Lewis RW, Mills IG, Bollag WB, Kumar MV (2011)
Novel role of androgens in mitochondrial fission and apoptosis
Mol Cancer Res. 2011, 9(8), 1067-77
»Abstract

Coward J, Kulbe H, Chakravarty P, Leader DA, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth JA, Vermeulin J, Singh N, Avril NE, Cummings J, Rexhepaj E, Jirstrom K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR (2011)
Interleukin-6 as a therapeutic target in human ovarian cancer.
Clin Cancer Res. 2011, 17(18), 6083-96
»Abstract

D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S (2011)
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Nat Med. 2011, 17(12), 1636-40
»Abstract

De Petris L, Brandén E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehtiö J. (2011)
Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer.
Eur J Cancer. 2011, 47(1), 131-7
»Abstract

Dean EJ, Cummings J, Roulston A, Berger M, Ranson M, Blackhall F, Dive C. (2011)
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Neoplasia. 2011 Apr 2011, 13(4), 339-47
»Abstract

Dhandayuthapani S, Perez HD, Paroulek A, Chinnakkannu P, Kandalam U, Jaffe M, Rathinavelu A (2011)
Bromelain-Induced Apoptosis in GI-101A Breast Cancer Cells
J Med Food 2011, , [Epub ahead of print]
»Abstract

Esaki Taito, Takashi Seto, Hiroshi Ariyama, Shuji Arita, Chinatsu Fujimoto, Koichiro Tsukasa, Takuro Kometani, Kaname Nosaki, Fumihiko Hirai, and Katsuro Yagawa (2011)
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors
Arch Drug Info 2011, 4(2), 23-31
»Abstract

Fayad W, Rickardson L, Haglund C, Olofsson MH, D'Arcy P, Larsson R, Linder S, Fryknäs M (2011)
Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties
Chem Biol Drug Des. 2011, 78(4), 547-57
»Abstract

Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. (2011)
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
J Clin Oncol. 2011, 29(7), 909-16
»Abstract

Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM, Radford J, Dive C. (2011)
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.
Br J Cancer 2011, 104(4), 719-25
»Abstract

Kudo C, Yamakoshi H, Sato A, Nanjo H, Ohori H, Ishioka C, Iwabuchi Y, Shibata H (2011)
Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo
BMC Pharmacol. 2011, 11, 4
»Abstract

Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H (2011)
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
Ann Oncol. 2011, 22(9), 2137-43
»Abstract

Mendoza RA, Moody EE, Enriquez MI, Mejia SM, Thordarson G (2011)
Tumorigenicity of MCF-7 human breast cancer cells lacking the p38α mitogen-activated protein kinase
J Endocrinol. 2011, 208(1), 11-9
»Abstract

Mendoza RA, Enriquez MI, Mejia SM, Moody EE, Thordarson G. (2011)
Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells.
J Endocrinol. 2011, 208(1), 40552
»Abstract

Olszewski-Hamilton U, Ausch C, Buxhofer-Ausch V, Hamilton G (2011)
Significance of Cytokeratin Fragment M65 and Cytokines IL6, IL8 and IL17A in Bone Marrow Aspirates of Colorectal Cancer Patients
British Journal of Medicine & Medical Research 2011, 1(4), 170-181
»Abstract

Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, Herbst RS, Eckhardt SG, Holland PM (2011)
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.
Br J Cancer 2011, 105(12), 1830-8
»Abstract

Pandey M, Kaur P, Shukla S, Abbas A, Fu P, Gupta S (2011)
Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study
Mol Carcinog 2011, , [Epub ahead of print]
»Abstract

Sebens S, Bauer I, Geismann C, Grage-Griebenow E, Ehlers S, Kruse ML, Arlt A, Schäfer H (2011)
Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection
J Biol Chem 2011, 286(47), 40911-21
»Abstract

Shin SJ, ung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB (2011)
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
Invest New Drugs 2011, , [Epub ahead of print]
»Abstract

Ulukaya E, Ari F, Dimas K, Sarimahmut M, Guney E, Sakellaridis N, Yilmaz VT (2011)
Cell death-inducing effect of novel palladium(II) and platinum(II) complexes on non-small cell lung cancer cells in vitro
J Cancer Res Clin Oncol. 2011, 137(10), 1425-34
»Abstract

Ulukaya E, Acilan C, Ari F, İkitimur E, Yilmaz Y (2011)
A Glance at the methods for detection of apoptosis qualitatively and quantitatively
Turk J Biochem 2011, 36(3), 261-269

Ulukaya E, Esra Karaagac1, Ferda Ari2, Arzu Y. Oral1, Saduman B. Adim3, Asuman H. Tokullugil1, Türkkan Evrensell (2011)
Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients.
Radiology and Oncology 2011, 45(2), 116-122

Wang Y, Zhao Y, Liu Y, Tian L, Jin D (2011)
Chamaejasmine inactivates Akt to trigger apoptosis in human HEp-2 larynx carcinoma cells.
Molecules 2011, 16, 8152-64
»Abstract

Bantel H, Simon HU. (2010)
DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria.
Cell Cycle. 2010, 9(14), 2710-1
»Abstract

Bhutani KK, Paul AT, Fayad W, Linder S. (2010)
Apoptosis inducing activity of steroidal constituents from Solanum xanthocarpum and Asparagus racemosus.
Phytomedicine. 2010, 17(10), 789-93
»Abstract

Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M. (2010)
Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Cancer Chemother Pharmacol 2010, , [Epub ahead of print]
»Abstract

Brandt D, Volkmann X, Anstätt M, Länger F, Manns MP, Schulze-Osthoff K, Bantel H. (2010)
Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas.
Eur J Cancer. 2010, 46(8), 1464-73
»Abstract

Brnjic S, Olofsson MH, Havelka AM, Linder S. (2010)
Chemical biology suggests a role for calcium signaling in mediating sustained JNK activation during apoptosis.
Mol Biosyst. 2010, 6(5), 767-74
»Abstract

Cummings J, Ward TH, Dive C. (2010)
Fit-for-purpose biomarker method validation in anticancer drug development.
Drug discov Today. 2010, 15(19-20), 816-25
»Abstract

Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, Greenhalf W, Ghaneh P, Neoptolemos JP. (2010)
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.
Br J Cancer 2010, 102(3), 577-582
»Abstract

Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M. (2010)
IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells.
Cancer Res. 2010, 70(23), 9611-20
»Abstract

Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Diéras V, Raymond E. (2010)
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
Eur J Cancer 2010, 46(18), 3243-50
»Abstract

Lickliter JD, Francesconi AB, Smith G, Burge M, Coulthard A, Rose S, Griffin M, Milne R, McCarron J, Yeadon T, Wilks A, Cubitt A, Wyld DK, Vasey PA (2010)
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
Br J Cancer 2010, 103(5), 597-606
»Abstract

Linder S, Olofsson MH, Herrmann R, Ulukaya E. (2010)
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
Expert Rev Mol Diagn. 2010, 10(3), 353-9
»Abstract

Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. (2010)
Serum M30 levels are associated with survival in advanced gastric carcinoma patients.
Int Immunopharmacol. 2010, 10(7), 719-22
»Abstract

Zhang L, Kavanagh BD, Thorburn AM, Camidge DR. (2010)
Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli.
Clin. Cancer Res. 2010, 16(17), 4478-89
»Abstract

Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, Hamilton G (2009)
Circulating Cytokeratin 18 Fragment M65-A Potential Marker of Malignancy in Colorectal Cancer Patients.
J Gastrointest Surg. 2009, 13(11), 43983
»Abstract

Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, Hamilton G. (2009)
Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
Eur J Surg Oncol. 2009, 35(11), 1164-8
»Abstract

Berndtsson M, Hernlund E, Shoshan MC, Linder S. (2009)
Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.
J Chem Biol. 2009, 2(2), 81-7
»Abstract

Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ. (2009)
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
Mol Cancer Ther. 2009, 8(8), 2122-30
»Abstract

Fayad W, Brnjic S, Berglind D, Blixt S, Shoshan MC, Berndtsson M, Olofsson MH, Linder S. (2009)
Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model.
Int J Cancer. 2009, 125(10), 2450-5
»Abstract

Fayad W, Fryknäs M, Brnjic S, Olofsson MH, Larsson R, Linder S. (2009)
Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.
PLoS One. 2009, 4(10), e7238
»Abstract

Fisher MB, Zhang XQ, McConkey DJ, Benedict WF. (2009)
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
Cancer Gene Ther. 2009, 16(7), 567-72
»Abstract

Franzen CA, Chen CC, Todorović V, Juric V, Monzon RI, Lau LF. (2009)
Matrix Protein CCN1 Is Critical for Prostate Carcinoma Cell Proliferation and TRAIL-Induced Apoptosis
Mol Cancer Res 2009, 7(7), 1045-55
»Abstract

Hernlund E, Kutuk O, Basaga H, Linder S, Panaretakis T, Shoshan M. (2009)
Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation
Free Radic Biol Med. 2009, 46(12), 1607-13
»Abstract

Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M. (2009)
Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment.
Mol Cancer Ther. 2009, 8(7), 1916-23
»Abstract

Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. (2009)
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
Am J Pathol. 2009, 175(2), 808-16
»Abstract

Kieback DG, (2009)
Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1.
In Vivo. 2009, 23(1), 77-80
»Abstract

Koelink PJ, Lamers CB, Hommes DW, Verspaget HW (2009)
Circulating cell death products predict clinical outcome of colorectal cancer patients.
BMC Cancer 2009, 9, 88
»Abstract

Koelink PJ, Mieremet-Ooms MA, Corver WE, Wolanin K, Hommes DW, Lamers CB, Verspaget HW. (2009)
5-Aminosalicylic Acid Interferes in the Cell Cycle of Colorectal Cancer Cells and Induces Cell Death Modes
Inflamm Bowel Dis 2009, 16(3), 379-89
»Abstract

Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW. (2009)
Clinical significance of stromal apoptosis in colorectal cancer.
Br J Cancer 2009, 101(5), 765-73
»Abstract

Koelink PJ, Lamers CB, Hommes DW, Verspaget HW. (2009)
Circulating cell death products predict clinical outcome of colorectal cancer patients.
BMC Cancer. 2009, , 23;9:88
»Abstract

Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H. (2009)
Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation
Carcinogenesis 2009, 30(9), 1517-27
»Abstract

Leal JF, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM. (2009)
Molecular pharmacology and antitumor activity of Zalypsis1 in several human cancer cell lines
Biochem Pharmacol 2009, 78(2), 162-70
»Abstract

Linder S, Alaiya A. (2009)
Serum efficacy biomarkers for oncology.
Biomark Med 2009, 3(1), 47-54
»Abstract

Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, Rundlöf AK, Fernandes AP, Björnstedt M, Dobra K. (2009)
Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
J Exp Clin Cancer Res. 2009, 29;28:92, 29;28:92.
»Abstract

Noreen F, Heinrich J, Moelling K. (2009)
Antitumor Activity of Small Double-Stranded Oligodeoxynucleotides Targeting Telomerase RNA in Malignant Melanoma Cells
Oligonucleotides 2009, 19(2), 169-78
»Abstract

Olofsson M H, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S (2009)
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
Cancer Biomark. 2009, 5(3), 117-25
»Abstract

Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. (2009)
Elevated Serum Levels of M30 and M65 in Patients with Locally Advanced Head and Neck Tumors.
Int Immunopharmacol. 2009, 9(5), 645-8
»Abstract

Pfeifer D, Wallin A, Holmlund B, Sun XF. (2009)
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells
J Cancer Res Clin Onco 2009, 135(11), 1583-92
»Abstract

Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R (2009)
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
Br J Cancer 2009, 101(3), 410-7
»Abstract

Ullen A, Schwarz S, Lennartsson L, Kalkner KM, Sandstrom P, Costa F, Lennernas B, Linder S, Nilsson S. (2009)
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.
Scand J Urol Nephrol. 2009, 43(2), 98-103
»Abstract

Carpinelli P, Moll J. (2008)
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers
Expert Opinion On Therapeutic Targets 2008, 12 (1), 69-80
»Abstract

Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, Culig Z (2008)
Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma
Adv Exp Med Biol. 2008, 617, 547-555
»Abstract

Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. (2008)
Biomarker method validation in anticancer drug development.
Br J Pharmacol 2008, 153(4), 646-656
»Abstract

Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH, Wilkinson RW, Growcott J, Hughes A, Dive C. (2008)
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Mol Cancer Ther. 2008, 7(3), 455-63
»Abstract

de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA. (2008)
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
Neoplasia 2008, 10 (10), 1041-8
»Abstract

Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D, Montie J, Sarkar FH, Shah RB, Hussain M (2008)
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer
The Journal of Urology 2008, 179 (3), 911-916
»Abstract

Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C. (2008)
Optimisation of circulating biomarkers of cell death for routine clinical use.
Ann Oncol. 2008, 19(5), 990-5
»Abstract

Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan MC. (2008)
Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir.
Int J Cancer. 2008, 123(2), 476-83
»Abstract

Herrmann R, Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S. (2008)
Screening for Compounds that Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids
J Biomol Screen 2008, 13(1), 39455
»Abstract

Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P. (2008)
Apoptosis and necrosis: detection, discrimination and phagocytosis.
Methods. 2008, 44 (3), 205-221
»Abstract

Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, Ward T, Rosenberg S, Dive C, Simpson K. (2008)
Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
Clin Cancer Res. 2008, 14(22), 7304-7310
»Abstract

Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008)
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Clin Cancer Res 2008, 14(3), 804-810
»Abstract

Strandberg Ihrlund L, Hernlund E, Khan O, Shoshan CM (2008)
3-Bromopyruvate as inhibitor of tumor cell energy metabolism and chemopotentiator of platinum drugs.
Molecular Oncology 2008, 2, 94-101
»Abstract

Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S (2007)
Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA.
Int J Cancer 2007, 120(1), 175-80
»Abstract

Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z. (2007)
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.
Oncogene. 2007, 26(20), 2822-32
»Abstract

Cummings J, Ranson M, Butt F, Moore D, Dive C (2007)
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
Cancer Chemother Pharmacol 2007, , 921-4
»Abstract

Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV. (2007)
8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Mol Pharmacol 2007, 72(5), 1137-45
»Abstract

Jackson C L, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M, Gao MY, Shirley RB, Stoffel MT, Vijay Kumar M, Mohnen D. (2007)
Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure.
Glycobiology 2007, ,
»Abstract

Jacob D A, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, Schumacher G, Lippert S, Neumann UP (2007)
Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
J Gastroenterol Hepatol 2007, 22(5), 738-48
»Abstract

Kronenberger B, Zeuzem S, Sarrazin c, Mihm U, von Wagnar M, Hofmann WP, Piiper A, Herrmann E (2007)
Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatits C.
Antivir Ther. 2007, 12(5), 779-87
»Abstract

Linder S, (2007)
Cytokeratin Markers Come of Age
Tumour Biol 2007, 28(4), 189-195
»Abstract

Olofsson M H, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. (2007)
Cytokeratin 18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy
Clin Cancer Res 2007, 13(11), 3198-3206 
»Abstract

Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M (2007)
The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival
Lung Cancer 2007, 56(3), 399-404
»Abstract

Voorzanger-Rousselot N, Garnero P (2007)
Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses
Cancer Treat Rev. 2007, 33 (3), 230-283
»Abstract

Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C.. (2006)
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
Br J Cancer 2006, 95, 42-48
»Abstract

Demiray M , Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, Manavoglu O. (2006)
Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study.
Cancer Invest 2006, 24(7), 669-76
»Abstract

Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, Mahoney J and Seiden MV (2006)
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Clin Cancer Res 2006, 12(22) , 6844-52
»Abstract

Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV. (2006)
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Clin Cancer Res 2006, 12(17), 5055-63
»Abstract

Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF (2006)
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
Mol Cancer Ther 2006, 5(4), 1079-86
»Abstract

Kaddour-Djebbar I, Lakshmikanthan V, Shirley RB, Ma Y, Lewis RW, Kumar MV (2006)
Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer.
Mol Cancer Ther 2006, 5(8), 1958-66
»Abstract

Kramer G, Schwartz, S., Hägg, M., Mandic Havelka, A. and Linder, S (2006)
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
Br J Cancer 2006, 94(11), 1592-8
»Abstract

Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV (2006)
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
Int J Cancer 2006, 119, 221-8
»Abstract

Leuhuber K, Klepal W, Hausott B, Marian B. (2006)
Apoptosis in a tissue-like culture model of human colorectal adenoma cells.
Tissue Cell. 2006, 38(3), 203-8
»Abstract

Ma Y, Lakshmikanthan, V., Lewis, R.W. and Kumar, M.V (2006)
Sensitization of TRAIL-restistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin.
Mol Cancer Ther 2006, 5(1) , 170-178
»Abstract

Pichon M F, Labroquere M, Rezai K, Lokiec F. (2006)
Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy
Anticancer Res 2006, 26(3B), 2387-92
»Abstract

Shoshan M, Mandic Havelka A, Neumann F and Linder S (2006)
Sense and sensibility: the use of cell death biomarker assays in high-throughput anticancer drug screening and monitoring treatment responses.
Expert Opin. Drug Discov 2006, Vol. 1 No. 6, 585-594

Shukla S, Gupta, S. (2006)
Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft.
Mol Cancer Ther 2006, 5(4) , 843-852
»Abstract

Welman A, Cawthorne C, Ponce-Perez L, Barraclough J, Danson S, Murray S, Cummings J, Allen TD, Dive C. (2006)
Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo.
Neoplasia 2006, 8(11), 906-16
»Abstract

Berndtsson M, Konishi Y, Bonni A, Hagg M, Shoshan M, Linder S, Havelka AM (2005)
Phosphorylation of BAD at Ser-128 during mitosis and paclitaxel-induced apoptosis.
FEBS Lett 2005, 579(14) , 3090-3094
»Abstract

Cummings J, Ward TH, Lacasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M and Dive C. (2005)
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Br J Cancer 2005, 92, 532-538
»Abstract

Erdal H, Berndtsson, M., Castro, J., Brunk, U., Shoshan, M.C. and Linder, S (2005)
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis.
Proc. Natl. Acad. Sci. USA 2005, 102, 192-197
»Abstract

Luciani P, Gelmini, S., Ferrante, E., Lania, A., Benvenuti, B., Baglioni, S., Mantovani, G., Cellai, I., Ammannati, F., Spada, A., Serio, M., Peri, A. (2005)
Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas
Jourlan of Clinical Endocrinology & Metabolism 2005, 11, 6156-6161
»Abstract

Lövborg H, Gullbo, J. and Larsson, R (2005)
Screening for apoptosis - classical and emerging techniques
Anticancer Drugs 2005, 16(6), 593-599
»Abstract

Shirley B S, Kaddour-Djebbar, I., Patel, D.M., Lakshmikanthan, V., Lewis, R.W. and Kumar, M.V. (2005)
Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells.
Neoplasia 2005, 7(12) , 1104-1111
»Abstract

Ueno T, Toi, M. and Linder, S (2005)
Detection of epithelial cell death in the body by cytokeatin 18 measurement.
Biomed&Pharmacotherapy 2005, , 359-362
»Abstract

Amantana A, London CA, Iversen PL, Devi GR. (2004)
X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells.
Mol Cancer Ther. 2004, 3(6), 699-707
»Abstract

Cummings J, Ward TH, Ranson M, Dive C. (2004)
Apoptosis pathway-targeted drugs - from the bench to the clinic.
Biochim Biophys Acta 2004, 1705(1), 53-66
»Abstract

Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. (2004)
Cimicifuga racemosa extract inhibits proliferation of estrogen
Breast Cancer Res Treat. 2004, 84(2), 151-60
»Abstract

Hägg M, Berndtsson, M., Mandic, A., Zhou, R., Shoshan, M.C., and Linder, S (2004)
Induction of ER stress by Ellipticine Plant Alkaloids.
Molecular Cancer Therapeutics 2004, 3, 489-497
»Abstract

Kramer G, Erdal, H., Mertens, H., Nap, M., Mauermann, J., Steiner, G., Marberger, M., Bivén, K., Shoshan, M.C. and Linder, S. (2004)
Differentiation between Cell Death Modes using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18.
Cancer Research 2004, 64, 1751-1756
»Abstract

Linder S, Havelka AM, Ueno T, Shoshan MC (2004)
Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.
Cancer Lett. 2004, 214,
»Abstract

Loaiza-Pérez A I, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT. (2004)
Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
Journal of Urology 2004, 171, 1688-1697
»Abstract

Muhl H, Paulukat J, Hofler S, Hellmuth M, Franzen R, Pfeilschifter J (2004)
The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.
Br J Pharmacol 2004, 143, 890-8
»Abstract

Schutte B, Henfling M, Kolgen W, Bouman M, Meex S, Leers MP, Nap M, Bjorklund V, Bjorklund P, Bjorklund B, Lane EB, Omary MB, Jornvall H, Ramaekers FC. (2004)
Keratin 8/18 breakdown and reorganization during apoptosis.
Exp Cell Res 2004, 297, 39412
»Abstract

Takada M, Kataoka A, Toi M, Bando H, Toyama K, Horiguchi S, Ueno T, Linder (2004)
A close association between alteration in growth kinetics by neoadjuvant
Int J Oncol. 2004, 25(2), 397-405
»Abstract

Bivén K, Erdal, H., Hägg, M., Ueno, T., Zhou, R., Lynch, M., Rowley, B., Wood, J., Zhang, C., Toi, M., Shoshan, M.C. and Linder, S. (2003)
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera.
Apoptosis 2003, 8, 263-268
»Abstract

Maloney E K, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, (2003)
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation
Cancer Res. 2003, 63(16), 5073-83
»Abstract

Thurnher D, Turhani, D., Pelzmann, M., Wannemacher, B., Knerer, B., Formanek, M., Wacheck, V. and Selzer, E. (2003)
Betulinic Acid: A new cytotoxic compound against malignant head & neck cancer cells.
Head & Neck 2003, 25(9), 732-740
»Abstract

Ueno T, Toi, M., Bivén, K., Bando, H., Ogawa, T. and Linder, S. (2003)
Measurement of an apoptosis product in the sera of breast cancer patients.
European Journal of Cancer; 2003, 39, 769-774
»Abstract

Hägg M, Bivén, K., Ueno, T., Rydlander, L, Björklund, P., Wiman, K.G., Shoshan, M.C. and Linder, S. (2002)
A novel high-through-put assay for screening of pro-apoptotic drugs.
Invest. New Drugs 2002, 20, 253-259
»Abstract

Mandic A, Viktorsson, K., Molin, M., Akusjärvi, G., Eguchi, H., Hayashi, S.‑I., Toi, M., Hansson, J., Linder, S. and Shoshan, M. (2001)
Cisplatin induces the pro-apoptotic conformation of Bak in a delta-MEKK1-dependent manner.
Mol Cell Biol 2001, 21, 3684-3691
»Abstract

Leers M P, Kölgen, W., Björklund, V., Bergman, T., Tribbick, G., Persson, B., Björklund, P., Ramaekers, F.C.S., Björklund, B., Nap, M., Jörnvall, H., and Schutte, B. (1999)
Immunocytochemical detection and mapping of a Cytokeratin 18 neo epitope exposed during early apoptosis.
J Pathol 1999, 187, 567-572
»Abstract